<DOC>
	<DOCNO>NCT01698918</DOCNO>
	<brief_summary>The purpose study find combine everolimus letrozole safe beneficial effect postmenopausal woman estrogen positive HER2 negative locally advanced metastatic breast cancer . Additionally , study aim find everolimus plus exemestane safe beneficial effect woman estrogen positive locally advanced metastatic breast cancer treatment everolimus plus letrozole . This study also aim find mouth rinse help reduce severity oral stomatitis , common side effect everolimus . This part study conduct country alcohol free 0.5mg/5ml dexamethasone oral solution commercially available .</brief_summary>
	<brief_title>Open-label , Phase II , Study Everolimus Plus Letrozole Postmenopausal Women With ER+ , HER2- Metastatic Locally Advanced Breast Cancer</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<mesh_term>Exemestane</mesh_term>
	<mesh_term>Letrozole</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<mesh_term>Ethanol</mesh_term>
	<criteria>Patients 18 year old great Patients metastatic locally advanced , unresectable breast cancer amenable curative treatment surgery radiotherapy Histological cytological confirmation estrogenreceptor positive ( ER+ ) human epidermal growth factor receptor 2 negative ( HER2 ) breast cancer Postmenopausal woman No prior treatment metastatic breast cancer Patients nonmeasurable lesion bone metastasis ( e.g. , pleural effusion , ascites , etc ) Patients receive prior hormonal systemic therapy metastatic breast cancer . Patients may receive prior neoadjuvant adjuvant endocrine therapy . In case neoadjuvant adjuvant NSAI ( letrozole/anastrozole ) therapy patient must complete therapy least 1 year prior study enrollment . Previous treatment mTOR inhibitor . Known hypersensitivity mTOR inhibitor , e.g. , sirolimus ( rapamycin ) . Other protocoldefined inclusion/exclusion criterion may apply</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>metastatic breast cancer , locally advanced breast cancer , HER2- , ER+ , everolimus , Afinitor</keyword>
</DOC>